Satraplatin: A new treatment option for patients with hormone refractory prostate cancer.

被引：0
|
作者：
Nathan, FE
Sternberg, C
Sartor, O
Petrylak, D
Witjes, F
Wosikowski, K
Petrone, ME
Rozencweig, M
机构：
[1] GPC Biotech Inc, Princeton, NJ USA
[2] San Camillo Hosp, Rome, Italy
[3] Forlanini Hosp, Rome, Italy
[4] LSU, Sch Med, New Orleans, LA USA
[5] Columbia Presbyterian Med Ctr, New York, NY 10032 USA
[6] Acad Ziekenhuis, Nijmegen, Netherlands
[7] GPC Biotech AG, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：453S / 453S
页数：1
相关论文
共 50 条
  • [1] Satraplatin in the treatment of hormone-refractory prostate cancer
    Sternberg, CN
    BJU INTERNATIONAL, 2005, 96 (07) : 990 - 994
  • [2] Satraplatin for hormone-refractory prostate cancer
    Kerr, Cathel
    LANCET ONCOLOGY, 2007, 8 (04): : 290 - 290
  • [3] Metastasizing hormone-refractory prostate cancer. Chemotherapy and new treatment approaches
    Wierecky, J.
    Bokemeyer, C.
    ONKOLOGE, 2007, 13 (08): : 726 - +
  • [4] Satraplatin in the treatment of hormone-refractory prostate cancer (vol 96, pg 990, 2005)
    Sternberg, CN
    BJU INTERNATIONAL, 2006, 97 (01) : 211 - 211
  • [5] Hormone-refractory prostate cancer: Choosing the appropriate treatment option
    Ross, Robert W.
    Kantoff, Philip W.
    ONCOLOGY-NEW YORK, 2007, 21 (02): : 185 - 193
  • [6] Satraplatin demonstrates clinical benefit in patients with advanced hormone-refractory prostate cancer: Results of the global phase III satraplatin and prednisone against refractory cancer (sparc) trial
    Sartor, O.
    Petrylak, D.
    Witjes, F.
    Berry, W.
    Chatta, G.
    Vaughn, D.
    Sternberg, C. N.
    CANCER INVESTIGATION, 2007, 25 : 19 - 20
  • [7] Satraplatin in patients with advanced hormone-refractory prostate cancer (HRPC): Overall survival (OS) results from the phase III satraplatin and prednisone against refractory cancer (SPARC) trial
    Sartor, A. O.
    Petrylak, D. P.
    Witjes, J. A.
    Berry, W. R.
    Chatta, G. S.
    Vaughn, D. J.
    Ferrero, J.
    Demkow, T.
    Eymard, J. C.
    Sternberg, C. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Current place of chemotherapy in the treatment of hormone-refractory metastatic prostate cancer.
    Breton, X
    Lechevallier, E
    Coulange, C
    PROGRES EN UROLOGIE, 2005, 15 (03): : 398 - 404
  • [9] Preclinical assessment of PSP-94 for the treatment of hormone refractory prostate cancer.
    Garde, SV
    Fraser, JE
    Chambers, AF
    Ilenchuk, TT
    CLINICAL CANCER RESEARCH, 1999, 5 : 3840S - 3840S
  • [10] Soy isoflavones and lycopene in the treatment of hormone-sensitive and hormone-refractory prostate cancer.
    Vaishampayan, UV
    Forman, JJ
    Hussain, M
    Cher, M
    Pontes, E
    Fontana, J
    Alluri, KC
    Doerge, D
    Sarkar, F
    Kucuk, O
    JOURNAL OF NUTRITION, 2004, 134 (05): : 1258S - 1258S
12345